CDK2 inhibitors at AACR: An answer to CDK4/6 resistance?

CDK4/6 inhibitors have cemented their role as practice-changing drugs for hormone receptor-positive, HER2-negative breast cancer, but resistance — both pre-existing and emergent — has always been a problem. With advances in medicinal chemistry and new modalities offering inroads into challenging targets, companies are turning to selective CDK inhibitors to overcome the problem. 

At the American Association of Cancer Research (AACR) Annual Meeting this month, AstraZeneca plc (LSE:AZN; NYSE:AZN) and NiKang Therapeutics Inc. each unveiled preclinical data for CDK2 inhibitors that have advanced into Phase I trials. At least three other companies presented preclinical research on previously disclosed therapies in the emerging drug class. ...